Newsbenzinga
Biohaven Completes Enrollment In RISE3 Trial To Evaluate Opakalim Channel Activator To Treat Refractory Focal Epilepsy
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…